Cite
HARVARD Citation
Vysotskaia, V. et al. (2020). Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations. Cancer. 126 (3), pp. 549-558. [Online].